GNTA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy...

Stats
今日成交量	1 684.00
平均成交量	5 968.00
市值	60.12M
EPS	$0 ( 2024-04-24 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.71
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2008-10-06	Driscoll Martin J	Buy	4 999	Options to acquire Common Stock
2008-04-11	Sanders Walter Lloyd	Buy	65 000	Restricted Stock Unit
2007-01-03	Sanders Walter Lloyd	Sell	53	Common Stock, par value $.001
2007-01-03	Sanders Walter Lloyd	Sell	51	Common stock, par value $.001
2007-07-11	Driscoll Martin J	Buy	30 000	Options to acquire Common Stock

INSIDER POWER
0.00
Last 60 transactions
Buy: 9 070 639 \| Sell: 19 095 969

Genenta Science S.p.A. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Genenta Science S.p.A. 财务报表

Annual	2023
营收:	$0
毛利润:	$-41 582.00 (0.00 %)
EPS:	$-0.630

FY	2023
营收:	$0
毛利润:	$-41 582.00 (0.00 %)
EPS:	$-0.630

FY	2022
营收:	$0
毛利润:	$-6 029.42 (0.00 %)
EPS:	$-0.200

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Genenta Science S.p.A. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Genenta Science S.p.A.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.